RetinAI Partners with MAXO to Advance Clinical Studies in Dry Eye Disease

Bern & Boston, US, September 9, 2024 - RetinAI U.S. Inc. (“RetinAI”), a leader in clinical and imaging data management software and AI-driven analytics for Ophthalmology, proudly announces a strategic partnership with MAXO, a reading center working closely with TFS HealthScience, a globally renowned Contract Research Organization (CRO). This collaboration is initially supporting two critical clinical studies in dry eye disease using RetinAI Discovery®, a state-of-the-art platform designed to enhance and expedite data workflows and clinical studies.

‍

The partnership ensures seamless delivery of these important studies with cutting-edge AI-enabled technologies. Both trials will leverage RetinAI's Discovery® platform, which offers a robust platform infrastructure for data upload, management, and imaging analysis. Discovery provides data security and facilitates real-time data sharing and collaboration on a single cloud-based platform, enabling global multicenter studies and monitoring of study progress among stakeholders. 

‍

Dr. Carlos Ciller, Chairman and CEO of Ikerian and CEO of RetinAI, expressed his enthusiasm for this collaboration:

“Our work with MAXO and TFS on these significant programs underscores our commitment to advancing clinical research and clinical trials in Ophthalmology. By integrating our Discovery platform, we aim to streamline data management and facilitate operations towards better study outcomes. We are dedicated to supporting CROs and Reading Centers by providing robust, user-friendly solutions that simplify data workflows in clinical trials. This collaboration is a testament to our continuous efforts to innovate and improve operations of clinical trials with efficient, intuitive technology.” 

‍

Dr. Bassem Saleh, CEO of TFS, stated:

This partnership with RetinAI and MAXO represents a significant advancement in our mission to deliver innovative solutions to our clients. By integrating cutting-edge AI-enabled technologies, we are not only enhancing the efficiency and accuracy of our clinical trials but also paving the way for transformative drug development. We are excited about the potential impact this collaboration will have on improving patient outcomes and advancing ophthalmology research.”

‍

About RetinAI Inc. US and Ikerian AG

Established in 2017, RetinAI (Part of Ikerian AG), develops software solutions to accelerate clinical, research and pharmaceutical workflows globally using advanced machine learning and computer vision.

‍Focused on the ophthalmology and optometry market, RetinAI builds tools to collect, organize and analyze health data from the eyes, enabling healthcare professionals to make the right decisions sooner in healthcare. RetinAI's international team leverages its clinical, technical, and scientific expertise to foster the transition from reactive to preventive medicine for severe eye diseases.

Follow RetinAI on LinkedInFollow Ikerian on LinkedinAbout RetinAI Discovery®‍

RetinAI Discovery® (‘Discovery’) is a software platform to enable the right decisions sooner based on evidence, AI-derived insights, automation & data. Discovery is a modular and certified (FDA - 510(K) / CE - MDR) medical image & data platform that digests data, works via the web browser in the cloud, enables precision analysis with proprietary AI models and transfer of medical data linked to the patient, connecting devices, data sources & decisions in a seamless and secure manner. Discovery is the workbench for healthcare professionals throughout the entire journey of the disease, facilitating decisions for better patient care.

‍

About TFS HealthScience

TFS HealthScience is a full-service, global Contract Research Organization (CRO) that supports biotechnology and pharmaceutical companies throughout their entire clinical development journey. In partnership with customers, we build solution-driven teams working towards a healthier future. Bringing together nearly 800 professionals, TFS delivers tailored clinical research services in more than 40 countries with flexible clinical development and strategic resourcing solutions across key therapeutic areas, including Dermatology, Immunology & Inflammatory Diseases, Internal Medicine, Neuroscience, Oncology & Hematology, and Ophthalmology. 

Detailed information about TFS and its business offerings can be obtained through www.tfscro.com

‍